Skip to main content

Table 3 Resistance comparing IM versus VLM patients

From: Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda

  IM VLM
  (N = 70) (N = 39)
NRTI mutations   
 Any TAMs 34 (49) 2 (5)
 1 TAMs 13 (19) 1 (3)
 2 TAMs 14 (20) 1 (3)
 3+ TAMs 7 (10) 0 (0)
41L 8 (11) 0 (0)
65R 1 (1) 3 (8)
67 N 11 (16) 1 (3)
70R 13 (19) 1 (3)
184I/V 61 (87) 19 (49)
210W 1 (1) 0 (0)
215F/Y 25 (36) 1 (3)
NNRTI mutations   
 Any NNRTI mutation 63 (90) 23 (59)
 90I 5 (7) 0 (0)
 98 G 5 (7) 0 (0)
101E 8 (11) 1 (3)
103N 23 (33) 10 (26)
 108I 10 (14) 2 (5)
 138A/G 3 (4) 0 (0)
 179D 1 (1) 0 (0)
181C/I 22 (31) 6 (15)
188L/H 3 (4) 1 (3)
190A/S 13 (19) 6 (15)
225H 6 (9) 0 (0)
230L 1 (1) 0 (0)
  1. Bold: major mutations.IM: Immunologically monitored; VLM: Virologically monitored; NRTI: nucleoside reverse transcriptase inhibitor; TAMS: thymidine analogue mutations; NNRTI: non-nucleoside reverse transcriptase inhibitor.